## 1. Session Overview

Time and date: 17:00–19:30, May 29, 2018 (Tuesday)

Location: Conference Room 602, 6F, Sysmex Corporation headquarters

Committee members: Kenji Tsujimoto(committee chair), Yasuhiro Oyama (committee deputy chair),

Muneo Yabuki, Mika Tochihara, Eiji Maruyama, Yoshifumi Matsumoto,

Katsuyuki Nakazawa, Takako Nakajima

Personal information manager: Kayo Akagi

Secretariat: Daisuke Usuki

(Honorifics omitted, underlined personnel absent)

	Research	Plan Number and Conte	ent	Joint	Division	Result	Remarks
				Collaborat	Performing		
				or Present			
1	2018-06	Research related to	New	Yes	ICH Business	Approved	Confirmation of research plan
		coagulation test			Development	with	and informed consent
						conditions	document. Language of
							presentation document revised.
2	2018-07	2018-07 Research related to New		Yes	Scientific Affairs	Approved	Approved in joint collaborators'
		coagulation test				with	ethics examination.
						conditions	Language of research plan
							revised.
							Confirmation of research plan.
3	2018-08	Evaluation of	New	Yes	Central	Approved	Approved in joint collaborators'
		lung cancer diagnosis			Research	with	ethics examination.
		method			Laboratories	conditions	
4	2018-09	Research related to	New	Yes	Central	Approved	Approved in joint collaborators'
		cytoscreening			Research	with	ethics examination.
					Laboratories	conditions	
5	2018-10	Evaluation of	New	No	Central	Approved	None
		cancer diagnosis			Research		
		method			Laboratories		
6	2018-11 Construction of New		New	No	Engineering 1	Approved	None
		traceability system					

	Research	Plan Number and Conte	Joint	Division	Result	Remarks	
				Collaborat	Performing		
			or Present				
7	2018-12	Application	New	No	Business	Approved	Language of presentation
	development of flow			Strategy	with	document and research plan	
	cytometer			Development	conditions	revised.	

## 1. Session Overview

Time and date: 17:00–18:30, July 13, 2018 (Friday)

Location: Conference Room 602, 6F, Sysmex Corporation headquarters

Committee members: Kenji Tsujimoto(committee chair), Yasuhiro Oyama (committee deputy chair),

Muneo Yabuki, Mika Tochihara, Eiji Maruyama, Yoshifumi Matsumoto,

Katsuyuki Nakazawa, Takako Nakajima

Personal information manager: Kayo Akagi

Secretariat: <u>Daisuke Usuki</u>

(Honorifics omitted, underlined personnel absent)

	Researd	ch Plan Number and Cor	ntent	Joint Collaborator Present	Division Performing	Result	Remarks
1	2018-17	Evaluation of	New	Yes	Scientific	Approved	Language of research plan
		hematology analyzer			Affairs	with	and other documents
						conditions	revised.
2	2018-18	Evaluation of	New	No	Engineering 2	Approved	None
		coagulation analyzer					
3	2018-19	Research related to	New	Yes	Technology	Approved	Approved in joint
		atopic dermatitis			Development	with	collaborators' ethics
		diagnosis method				conditions	examination.
4	2018-20	Research related to	New	Yes	Engineering 1	Approved	Approved in joint
		coagulation test				with	collaborators' ethics
						conditions	examination.
5	2018-21	Research related to	New	Yes	Engineering 1	Approved	Approved in joint
		coagulation test				with	collaborators' ethics
						conditions	examination.
6	2017-30	Research related to	Renewal	Yes	Clinical	Approved	Approved in joint
		testing for diabetes			Innovation	with	collaborators' ethics
		mellitus				conditions	examination.

## 1. Session Overview

Time and date: 17:00–18:40, Seputember 18, 2018 (Tuesday)

Location: Conference Room 602, 6F, Sysmex Corporation headquarters

Committee members: Kenji Tsujimoto(committee chair), Yasuhiro Oyama (committee deputy chair),

Muneo Yabuki, Mika Tochihara, Eiji Maruyama, Yoshifumi Matsumoto,

Katsuyuki Nakazawa, Takako Nakajima

Personal information manager: Kayo Akagi

Secretariat: Daisuke Usuki

(Honorifics omitted, underlined personnel absent)

	Research I	Plan Number and Con	tent	Joint Collaborator Present	Division Performing	Result	Remarks
1	2018-26	Evaluation of hematology analyzer	New	Yes	Engineering 1	Approved with conditions	Language of presentation document revised.
2	2018-27	Evaluation of hematology analyzer	New	Yes	Engineering 1	Approved with conditions	Language of presentation document and research plan revised.
3	2018-28	Research related to urinalysis analyzer	New	Yes	Scientific Affairs	Re- examine	Language of research plan revised.
4	2018-29	Research related to coagulation test	New	Yes	ICH Business Development	Approved with conditions	Approved in joint collaborators' ethics examination.  Language of presentation document and research plan revised.
5	2018-30	Software development of hematology analyzer	New	No	HU Business  Development	Approved	Language of presentation document and research plan revised.
6	2018-31	Performance evaluation of hematology analyzer	New	No	Manufacturing Management	Approved with conditions	Language of presentation document and research plan revised.

	Research I	Plan Number and Con	tent	Joint Collaborator Present	Division Performing	Result	Remarks
7	2018-32	Evaluation of New cancer diagnosis method		No	Central Research Laboratories	Approved with conditions	Language of presentation document and research plan revised.
8	2017-82			No	Scientific Affairs	Re- examine	Language of research plan revised.

## 1. Session Overview

Time and date: 17:00–18:30, November 21, 2018 (Wednesday)

Location: Conference Room 602, 6F, Sysmex Corporation headquarters

Committee members: Kenji Tsujimoto(committee chair), Yasuhiro Oyama (committee deputy chair),

Muneo Yabuki, Mika Tochihara, Eiji Maruyama, Yoshifumi Matsumoto,

Katsuyuki Nakazawa, Takako Nakajima

Personal information manager: Kayo Akagi Secretariat: Daisuke Usuki

(Honorifics omitted, underlined personnel absent)

F	Research P	lan Number and Conto	ent	Joint Collaborator Present	Division Performing	Result	Remarks
1	2018-37	Research of	New	Yes	Business	Approved	Language of presentation
		hematology analyzer			Strategy		document and research plan
					Development		revised.
							Approved in joint collaborators'
							ethics examination.
2	2018-38 Evaluation of New		New	Yes	Engineering 1	Approved	Approved in joint collaborators'
		immunochemistry				with	ethics examination.
		reagent				conditions	Language of informed consent
							document revised.
3	2018-39	Evaluation of	New	No	Engineering 1	Approved	Language of informed
		coagulation reagent					consent document revised.
4	2018-40 Application New		New	No	Scientific	Approved	Languageof presentation
	development of flow				Affairs		document and research plan
		cytometer					revised.

## 1. Session Overview

Time and date: 17:00–18:30, January 23, 2019 (Wednesday)

Location: Conference Room 602, 6F, Sysmex Corporation headquarters

Committee members: Kenji Tsujimoto(committee chair), Yasuhiro Oyama (committee deputy chair),

Muneo Yabuki, Mika Tochihara, Eiji Maruyama, Yoshifumi Matsumoto,

Katsuyuki Nakazawa, Takako Nakajima

Personal information manager: Kayo Akagi

Secretariat: Daisuke Usuki

(Honorifics omitted, underlined personnel absent)

	Research	n Plan Number and Conte	ent	Joint Collaborator Present	Division Performing	Result	Remarks
1	2017-28	Research related to New breast cancer diagnosis method		Yes	LS Business	Approved	None
2	2018-47	Evaluation of New cancer diagnosis method		Yes	Central Approved Research Laboratories		Approved in joint collaborators'ethics examination.
3	2018-48	Research related to urinalysis analyzer	New	Yes	Scientific Affairs	Approved	Language of research plan and informed consent document revised.
4	4 2018-49 Evaluation of new primary care products		New	Yes	Business Strategy Development	Approved	Approved in joint collaborators'ethics examination.  Language of presentation document and research plan revised.

## 1. Session Overview

Time and date: 17:00–20:45, March 1, 2018 (Friday)

Location: Conference Room 602, 6F, Sysmex Corporation headquarters

Committee members: Kenji Tsujimoto(committee chair), Yasuhiro Oyama (committee deputy chair),

Muneo Yabuki, Mika Tochihara, Eiji Maruyama, Yoshifumi Matsumoto,

Katsuyuki Nakazawa, Takako Nakajima

Personal information manager: Kayo Akagi

Secretariat: Daisuke Usuki

(Honorifics omitted, underlined personnel absent)

	Research Plan Number and Content			Joint Collaborator Present	Division Performing	Result	Remarks
1	2018-52	Evaluation of hematology analyzers and reagents	New	Yes	Engineering 1	Approved	Approved in joint collaborators' ethics examination.
2	2018-53	Evaluation of urinalysisanalyzer and reagent	New	Yes	Engineering 2	Approved	Approved in joint collaborators' ethics examination.
3	2018-54	Evaluation of immunochemistry analyzer and reagent	New	Yes	Engineering 1	Approved	Approved in joint collaborators' ethics examination.
4	2018-55	Evaluation of coagulation analyzer	New	Yes	Engineering 2	Approved	Approved in joint collaborators' ethics examination.
5	2018-56	Evaluation of hematology analyzer	New	No	Engineering 1	Re- examine	Language of research plan revised.
6	2018-57	2018-57 Evaluation of New hematology analyzer		No	Engineering 1	Re- examine	Language of research plan revised.
7	2018-58 Evaluation of New immunochemistry reagent		No	Engineering 1	Approved	Language of research plan revised.	

	Research	Plan Number and Co	ntent	Joint Collaborator Present	Division Performing	Result	Remarks
8	2018-59	Evaluation of immunochemistry reagent	New	No	Engineering 1	Approved	None
9	2018-60	Evaluation of immunochemistry reagent	New	No	Engineering 1	Approved	Language of informed consent document revised.
10	2018-61	Ensuring and verification of standard analyzers traceability	New	No	Scientific Affairs	Approved	None
11	2018-62	Evaluation of the next reference counter	New	No	Scientific Affairs	Approved	Language of informed consent document revised.
12	2018-63	Verification of standard analyzers traceability	New	No	Scientific Affairs	Approved	Language of informed consent document revised.
13	2018-64	Evaluation of coagulation reagent	New	No	Sysmex International Reagents Corporation	Approved	Language of informed consent document revised.
14	2018-65	Evaluation of coagulation reagent	New	No	Sysmex International Reagents Corporation	Approved	Language of research plan and informed consent document revised.
15	2018-66	Verification of standard analyzers traceability	New	No	Clinical Innovation	Approved	Language of presentation document and research plan and informed concent document revised.
16	2018-67	Evaluation of cancer diagnosis method	New	No	Clinical Innovation	Approved	Language of informed consent document revised.
17	2018-68	Evaluation of gene testing technologies	New	No	LS Business	Approved	Language of presentation document and research plan revised.

	Research	Plan Number and Co	ntent	Joint Collaborator Present	Division Performing	Result	Remarks
18	2018-69	Research related to stomach cancer diagnosis method	New	Yes	LS Business	Approved with conditions	Approved in joint collaborators' ethics examination.  Language of presentation document and research plan revised.
19	2018-70	Research related to colon cancer diagnosis method	New	Yes	LS Business	Approved with conditions	Approved in joint collaborators' ethics examination.  Language of presentation document and research plan revised.
20	2018-71	Research related to Hematopoietic stem cell transplantation diagnosis method	New	Yes	Central Research Laboratories	Approved with conditions	Approved in joint collaborators' ethics examination.
21	2018-72	Research related to atopic dermatitis diagnosis method	New	Yes	Technology  Development	Approved	None
22	2018-73	Research related to Improve the performance of medical antibodies	New	Yes	Technology Strategy	Approved with conditions	Approved in joint collaborators' ethics examination.
23	2018-74 Research related to New cancer diagnosis method		Yes	Technology Strategy	Approved with conditions	Approved in joint collaborators' ethics examination.	

# Rapid Screening Results, Research Ethics Examination Committee, Sysmex Corporation

	Rese	earch Plan Number and Content		Joint Coll abor ator Pres ent	Joint Collaborator Present	Examin ation period	Result	Remarks
1	2018-01	Evaluation of coagulation analyzer	New	Yes	Engineering 2	2018/4/5 ~4/10	Approved	None
2	2018-02	Evaluation of gene testing technologies	New	Yes	LS Business	2018/4/6 ~4/12	Approved	None
3	2018-03	Evaluation of gene testing technologies	New	Yes	LS Business	2018/4/6 ~4/12	Approved	None
4	2018-04	Evaluation of coagulation analyzer	New	Yes	Engineering 2	2018/4/2 5~5/11	Approved	None
5	2018-05	Research related to urinalysis analyzer	New	Yes	Engineering 2	2018/4/2 6~ 2018/5/1	Approved	None
6	2018-13	Evaluation of immunochemistry reagent	New	Yes	Engineering 1	2018/5/7 ~5/11	Approved	None
7	2018-15	Evaluation of immunochemistry reagent	New	Yes	Engineering 1	2018/5/3 1~6/15	Approved	None
8	2018-16	Evaluation of cervical cancer screening system	New	Yes	Clinical Innovation	2018/6/1 ~6/15	Approved	None
9	2018-14	Evaluation of immunochemistry reagent	New	Yes	Engineering 1	2018/5/3 1~6/22	Approved	None
10	2018-22	Evaluation of coagulation analyzer	New	Yes	Engineering 2	2018/7/4 ~7/10	Approved	None
11	2018-23	Application development of flow cytometer	New	Yes	Engineering 1	2018/7/1 9~ 2020/9/2 4	Approved	None
12	2018-24	Evaluation of hematology analyzer	New	Yes	Scientific Affairs	2018/7/2 3~8/22	Approved	None
13	2018-25	Research related to coagulation test	New	Yes	Engineering 1	2018/8/2 ~8/22	Approved	None

	Rese	earch Plan Number and Content		Joint Coll abor ator Pres	Joint Collaborator Present	Examin ation period	Result	Remarks
				ent				
14	2018-33	Research related to coagulation	New	Yes	Engineering 1	2018/8/2	Approved	None
		test				3~9/7		
15	2018-34	Evaluation of immunochemistry	New	Yes	Engineering 1	2018/9/7	Approved	None
		reagent				~10/2		
16	2018-35	Research related to lung cancer	New	Yes	Central Research	2018/9/2	Approved	None
		diagnosis method			Laboratories	8~		
						10/10		
17	2018-36	Research related to coagulation	New	Yes	Engineering 1	2018/10/	Approved	None
		test				22~		
						10/29		
18	2018-41	Research related to coagulation	New	Yes	Engineering 1	2018/10/	Approved	None
		test				26~		
						10/29		
19	2018-42	Evaluation of lung cancer diagnosis	New	Yes	Clinical Innovation	2018/11/	Approved	None
		method				12~		
						11/19		
20	2018-43	Evaluation of lung cancer diagnosis	New	Yes	LS Business	2018/11/	Approved	None
		method				16~		
						11/27		
21	2018-44	Research related to	New	Yes	Technology Strategy	2018/11/	Approved	None
		kidney disease diagnosis method				28~		
						12/5		
22	2018-45	Research related to coagulation	New	Yes	Engineering 1	2018/12/	Approved	None
		test				7~		
						12/13		
23	2018-46	Evaluation of coagulation reagent	New	Yes	Engineering 1	2018/12/	Approved	None
						10~		
						12/13		
24	2018-43	Evaluation of lung cancer diagnosis	New	Yes	LS Business	2018/12/	Approved	None
		method				18~		
						12/26		

Research Plan Number and Content				Joint Coll abor ator Pres ent	Joint Collaborator Present	Examin ation period	Result	Remarks
25	2018-50	Evaluation of gene testing technologies	New	Yes	LS Business	2018/12/ 25~	Approved	None
						2019/1/9		
26	2018-51	Evaluation of coagulation reagent	New	Yes	Engineering 1	2019/1/7	Approved	None
						~1/11		
27	2018-43	Evaluation of lung cancer diagnosis	New	Yes	LS Business	2019/1/2	Approved	None
		method				4~1/30		
28	2018-77	Research related to	New	Yes	HU Business	2019/2/6	Approved	None
		urinalysis analyzer			Development	~2/13		
29	2018-75	Research related to colon cancer	New	Yes	LS Business	2019/2/6	Approved	None
		diagnosis method				~2/18		
30	2018-76	Research related to colon cancer	New	Yes	LS Business	2019/2/6	Approved	None
		diagnosis method				~2/18		
31	2018-79	Research related to utilization of	New	Yes	Business Strategy	2019/2/2	Approved	None
		clinical test data			Development	6~3/1		
32	2018-50	Evaluation of gene testing	New	Yes	LS Business	2019/3/5	Approved	None
		technologies				~3/13		
33	2018-80	Evaluation of hematology analyzer	New	Yes	Engineering 1	2019/3/2	Approved	None
						0~3/28		
34	2018-81	Research related to coagulation	New	Yes	Engineering 1	2019/3/2	Approved	None
		test				0~3/28		